Avicena issued U.S. creatine patent

Avicena Group has announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 7,186,754, entitled, "Use of Creatine or Creatine Compounds for Skin Preservation," on March 6, 2007.

The newly issued patent contains claims which cover methods and compositions for treating uneven skin pigmentation using a topical application of creatine and carnitine.

This patent enhances the Company's skin care patent portfolio, which also contains U.S. Patent No. 6,242,491, with claims directed to methods for treating skin damage resulting from sun radiation, stress, fatigue or free radicals by administering creatine.

"We are extremely pleased to have received this additional patent claim to broaden our IP position in dermaceuticals," stated Dr. Belinda Tsao- Nivaggioli, Avicena's Chief Executive Officer.

Dr. Tsao-Nivaggioli continued, "The discovery that a composition of creatine and carnitine is an effective treatment for uneven skin pigmentation provides a new approach to a very common dermatological problem."